KRAS and colorectal carcinoma: The clinical and molecular parameters in the CoMet samples, including gender, CRC anatomical location, and mutation frequency of TP53 and APC are in accordance with the CMS2 profile, while KRAS mutations were more frequent in the CoMet cohort compared what is typically found in CMS2.